% alzhub.org library filter % Source: https://alzhub.org/research?institution=I4210151718&design=trial % 16 entries, in the order the page lists them. Built from alzhub.org's own records. % 0 entries have no readable author in the source record and carry no author field. @article{swanson2021-33865446, author = {Swanson, C. J. and Zhang, Y. and Dhadda, S. and Wang, J. and Kaplow, J. and Lai, R. Y. K. and Lannfelt, L. and Bradley, H. and others}, title = {{A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody}}, journal = {Alzheimer's research \& therapy}, year = {2021}, doi = {10.1186/s13195-021-00813-8}, pmid = {33865446}, url = {https://doi.org/10.1186/s13195-021-00813-8} } @article{vandyck2023-36449413, author = {van Dyck, C. H. and Swanson, C. J. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and Kanekiyo, M. and Li, D. and others}, title = {{Lecanemab in Early Alzheimer's Disease}}, journal = {The New England journal of medicine}, year = {2023}, doi = {10.1056/nejmoa2212948}, pmid = {36449413}, url = {https://doi.org/10.1056/nejmoa2212948} } @article{honig2024-38730496, author = {Honig, L. S. and Sabbagh, M. N. and van Dyck, C. H. and Sperling, R. A. and Hersch, S. and Matta, A. and Giorgi, L. and Gee, M. and others}, title = {{Updated safety results from phase 3 lecanemab study in early Alzheimer's disease}}, journal = {Alzheimer's research \& therapy}, year = {2024}, doi = {10.1186/s13195-024-01441-8}, pmid = {38730496}, url = {https://doi.org/10.1186/s13195-024-01441-8} } @article{teng2022-35696185, author = {Teng, E. and Manser, P. T. and Pickthorn, K. and Brunstein, F. and Blendstrup, M. and Sanabria Bohorquez, S. and Wildsmith, K. R. and Toth, B. and others}, title = {{Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial}}, journal = {JAMA neurology}, year = {2022}, doi = {10.1001/jamaneurol.2022.1375}, pmid = {35696185}, url = {https://doi.org/10.1001/jamaneurol.2022.1375} } @article{shcherbinin2022-36094645, author = {Shcherbinin, S. and Evans, C. D. and Lu, M. and Andersen, S. W. and Pontecorvo, M. J. and Willis, B. A. and Gueorguieva, I. and Hauck, P. M. and others}, title = {{Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial}}, journal = {JAMA neurology}, year = {2022}, doi = {10.1001/jamaneurol.2022.2793}, pmid = {36094645}, url = {https://doi.org/10.1001/jamaneurol.2022.2793} } @article{devanand2026-41405855, author = {Devanand, D P and Wisniewski, Thomas and Razlighi, Qolamreza and Qian, Min and Wei, Renjie and Andrews, Howard F and Acosta, Edward P and Bell, Karen L and others}, title = {{Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial}}, journal = {JAMA}, year = {2026}, doi = {10.1001/jama.2025.21738}, pmid = {41405855}, url = {https://doi.org/10.1001/jama.2025.21738} } @article{rogers1998-9588436, author = {Rogers, S. L. and Doody, R. S. and Mohs, R. C. and Friedhoff, L. T.}, title = {{Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group}}, journal = {Archives of internal medicine}, year = {1998}, doi = {10.1001/archinte.158.9.1021}, pmid = {9588436}, url = {https://doi.org/10.1001/archinte.158.9.1021} } @article{geldmacher2003-12834513, author = {Geldmacher, D. S. and Provenzano, G. and McRae, T. and Mastey, V. and Ieni, JR.}, title = {{Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease}}, journal = {Journal of the American Geriatrics Society}, year = {2003}, doi = {10.1046/j.1365-2389.2003.51306.x}, pmid = {12834513}, url = {https://doi.org/10.1046/j.1365-2389.2003.51306.x} } @article{kishnani2009-19606472, author = {Kishnani, P. S. and Sommer, B. R. and Handen, B. L. and Seltzer, B. and Capone, G. T. and Spiridigliozzi, G. A. and Heller, J. H. and Richardson, S. and others}, title = {{The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome}}, journal = {American journal of medical genetics. Part A}, year = {2009}, doi = {10.1002/ajmg.a.32953}, pmid = {19606472}, url = {https://doi.org/10.1002/ajmg.a.32953} } @article{berry2023-37040116, author = {Berry, D. A. and Dhadda, S. and Kanekiyo, M. and Li, D. and Swanson, C. J. and Irizarry, M. and Kramer, L. D. and Berry, S. M.}, title = {{Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial}}, journal = {JAMA network open}, year = {2023}, doi = {10.1001/jamanetworkopen.2023.7230}, pmid = {37040116}, url = {https://doi.org/10.1001/jamanetworkopen.2023.7230} } @article{rogers2000-10793322, author = {Rogers, S. L. and Doody, R. S. and Pratt, R. D. and Ieni, JR.}, title = {{Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study}}, journal = {European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology}, year = {2000}, doi = {10.1016/s0924-977x(00)00067-5}, pmid = {10793322}, url = {https://doi.org/10.1016/s0924-977x(00)00067-5} } @article{rogers1998-9452942, author = {Rogers, S. L. and Friedhoff, L. T.}, title = {{Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study}}, journal = {European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology}, year = {1998}, doi = {10.1016/s0924-977x(97)00079-5}, pmid = {9452942}, url = {https://doi.org/10.1016/s0924-977x(97)00079-5} } @article{vandyck2025-41355080, author = {van Dyck, C. H. and Sperling, R. and Johnson, K. and Dhadda, S. and Kanekiyo, M. and Li, D. and Gee, M. and Hersch, S. and Irizarry, M. and Kramer, L.}, title = {{Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension study}}, journal = {Alzheimer's \& Dementia}, year = {2025}, doi = {10.1002/alz.70905}, pmid = {41355080}, url = {https://doi.org/10.1002/alz.70905} } @article{chen2025-40189473, author = {Chen, Christopher and Katayama, Sadao and Lee, Jae Hong and Lee, Jun-Young and Nakagawa, Masaki and Torii, Kentaro and Ogawa, Tomoo and Dash, Amitabh and others}, title = {{Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease}}, journal = {The Journal of Prevention of Alzheimer s Disease}, year = {2025}, doi = {10.1016/j.tjpad.2025.100160}, pmid = {40189473}, url = {https://doi.org/10.1016/j.tjpad.2025.100160} } @article{bhagunde2026-41543367, author = {Bhagunde, Pratik R. and Penner, Natasha and Willis, Brian A. and Bell, Robert and Charil, Arnaud and Irizarry, Michael C. and Hersch, Steven J. and Reyderman, Larisa}, title = {{Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR ‐ SB Utilizing Semi‐Mechanistic Model}}, journal = {CPT Pharmacometrics \& Systems Pharmacology}, year = {2026}, doi = {10.1002/psp4.70173}, pmid = {41543367}, url = {https://doi.org/10.1002/psp4.70173} } @article{doherty2022-35622461, author = {Doherty, T. and Gee, M. and Maruff, P. and Smith, R. and Murphy, J. and Marsh, J. and Koschalka, L. and Martinez, M. and others}, title = {{Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease: The Cognitive Task Force}}, journal = {Alzheimer disease and associated disorders}, year = {2022}, doi = {10.1097/wad.0000000000000508}, pmid = {35622461}, url = {https://doi.org/10.1097/wad.0000000000000508} }